An observational study in Renal Artery Fibromuscular Dysplasia, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Shanghai Jiao Tong University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · Shanghai Jiao Tong University School of Medicine.
Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, this one is one of 3 that started in 2021, is one of 2 observational ones, and was the 9th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Shanghai Jiao Tong University School of Medicine
Ages 18–75
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine
Ages 65–84 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 320 across the 13 interventional studies, 567 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.
4 of the studies in Hypertension by Shanghai Jiao Tong University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735444Shanghai Jiao Tong University School of MedicineProspective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China | 2026-12 |
| NCT06790927Shanghai Jiao Tong University School of MedicineStandardized Antihypertensive Treatment Protocol | 2026-12-31 |
| NCT05363748Shanghai Jiao Tong University School of MedicineRenal Artery Fibromuscular Dysplasia Registry | 2026-12-31 |
| NCT05530083Shanghai Jiao Tong University School of MedicineGroup Education Helps Smoking Cessation and Hypertension Control | 2027-01-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Hypertension by Shanghai Jiao Tong University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
patients with renal artery fibromuscular dysplasia who signed the informed consent will be eligible. The following patients are eligible for inclusion: 1) Patients with established renal artery FMD, at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). 2) Patients with so-called "atypical FMD" or "FMD-like presentation", i.e. patients presenting with at least one dissection or 2 aneurysms \< 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy. 3) Children with renal artery FMD may be also included, provided they meet the inclusion criteria and there is no evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sequential
The percentage of focal or multifocal FMD
The percentage of focal or multifocal subtype in the renal artery FMD in China
Time frame: 1 day
The percentage of multivessel FMD in the renal artery FMD
The percentage of multivessel FMD in the renal artery FMD in China
Time frame: 1 week
The change of blood pressure
Comparison of blood pressure between baseline and 3/6/12 months (every year) after percutaneous transluminal angioplasty.
Time frame: 10 years
The rate of restenosis of renal artery FMD
The rate of restenosis of renal artery FMD after percutaneous transluminal angioplasty
Time frame: 10 years
The rate of incidence of cardiovascular events
The rate of incidence of cardiovascular events in the renal artery FMD patients, such as cerebral infarction, hypertensive nephropathy, myocardial infarction and so on.
Time frame: 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Dec 2026, 62 months after the start.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 62 months is above that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University School of Medicine →